30년 임상 누빈 종양내과전문의, 이뮨온시아 IPO 이끈다
[Korean News] http://www.thebell.co.kr/free/content/ArticleView.asp?key=202204131406144160105431&svccode=00&page=1&sort=thebell_check_time
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors | SpringerLink
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China
[English News] ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China (prnewswire.com) [Korean News] 유한양행이 점찍은 이뮨온시아, '5400억원' 항암신약 기술수출 - 머니투데이 (mt.co.kr)